<DOC>
	<DOCNO>NCT01264341</DOCNO>
	<brief_summary>The purpose study determine whether combination bevacizumab/temsirolimus effective patient advance renal carcinoma progress anti-VEGF treatment</brief_summary>
	<brief_title>Efficacy Safety Bevacizumab/Temsirolimus Combination Treat Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Adult patient ( 18th year age complete ) Signed date write informed consent form prior procedure relate protocol . Histologically confirm advanced clear cell renal cancer . Measurable disease . Failure first line antiVEGF treatment . Performance status 02 , accord Eastern Cooperative Oncology Group ( ECOG ) . Satisfactory hematological parameter : White blood cell count &gt; 4000 mm3 . Platelet count 100000/mm3 . Neutrophil blood cell count &gt; 1200/ mm3 . Hemoglobin &gt; 9,0 g/dL ( achieve red blood cell transfusion ) . Satisfactory biochemical parameter : Serum creatinine &lt; 2 x Upper Limit Normal ( ULN ) Aspartate Aminotransferase ( AST ) &lt; 2,5 x ULN Alanine Transaminase ( ALT ) &lt; 2,5 x ULN . Bilirubin &lt; 2 x ULN ( For female patient ) Absence pregnancy ( negative pregnancy test woman reproductive age enrollment ) . ( For female patient ) Nonlactating woman . Use efficient contraceptive measure ( woman men ) prevent possible pregnancy female patient female partner male patient treatment 6 month end treatment . Prior treatment mTOR inhibitor . Major surgery ( include open biopsy ) insufficient recovery existence major trauma within 4 week enrollment . Uncontrolled hypertension . Active infection require systemic treatment within 4 week prior enrollment . Minor surgery ( instance , catheter placement ) within 2 day enrollment . Scheduled major surgery within treatment period . Medical history last 6 month prior enrollment significant cardiovascular disease , diabetes , cardiac infarction , unstable angina , uncontrolled arrhythmia significant heart failure . Indications uncontrolled metastasis disease progression CNS lesion ( suspicion uncontrolled metastasis disease progression eliminate image technique within 14 day prior enrollment ) . Medical history last 5 year prior enrollment malignancy ( exclude basal squamous skin cell carcinoma situ carcinoma cervix ) . History nonhealing wound include active gastric ulcer . History fistula last 6 month prior enrollment . History gastrointestinal perforation . Patient incapacity ( psychiatric social reason ) conform protocol . History hemorrhagic predisposition . History hypersensitivity medication investigation . Significant proteinurea . Prior immunotherapy within 4 week prior enrollment . Prior radiation treatment within 2 week prior enrollment . Concomitant medication inducer strong inhibitor coenzyme CYP3A4 ( see Appendix 5 indicative list active compound ) . Concurrent participation interventional clinical trial investigational medicinal product . History chronic interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>